BHCNYSEPharmaceutical PreparationsFiscal year ends December 31

Bausch Health Companies Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$6.32+0.02 (+0.32%)

Close on Oct 19, 2026

Market cap: $2.39B
P/E (TTM): –
Dividend yield: –

Bausch Health Companies Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	10,266	9,625	8,757	8,124	8,434	8,027	8,601	8,380	8,724	9,674	10,447	8,206	5,770	3,480	2,427	1,181	820	757
Cost of Revenue	–	–	–	–	–	–	–	–	2,506	2,572	2,532	2,178	1,846	905	684	396	204	197
Gross Profit	–	–	–	–	–	–	–	–	6,218	7,102	7,915	6,028	3,923	2,575	1,744	786	616	560
Research & Development	629	616	604	529	465	452	471	413	361	421	334	246	157	79	66	68	48	70
Selling, General & Admin	3,438	3,296	2,917	2,625	2,624	2,367	2,554	2,473	2,582	2,810	2,700	2,026	1,305	756	572	277	168	189
Advertising Expenses	766	786	625	518	515	451	544	481	462	564	652	435	277	158	106	30	10	–
Total Costs & Expenses	8,453	8,079	7,794	7,670	7,984	7,351	8,804	10,764	8,622	10,240	8,920	6,205	6,179	3,401	2,127	1,291	639	633
Operating Income	1,813	1,546	963	454	450	676	-203	-2,384	102	-566	1,527	2,001	-410	80	300	-110	181	124
Interest Expense	1,604	1,388	1,328	1,464	1,426	1,534	1,612	1,685	1,840	–	–	–	–	–	–	–	–	–
Interest & Investment Income	48	33	26	14	7.00	13	12	11	12	8.00	4.00	5.00	8.00	6.00	4.08	1.29	1.12	9.40
Other Non-Operating Income	-142	-247	-28	-35	-373	-502	-1,426	20	348	-73	-295	263	–	–	–	–	–	–
Merger & Restructuring Charges	–	–	–	–	–	22	31	22	52	132	362	382	462	267	98	141	30	70
Asset Impairment Charges	145	29	54	15	234	114	75	568	714	422	304	145	–	–	–	12	25	69
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	0	0	293	5.80	2.10	23	-5.55	18	-4.53
Gain (Loss) on Sale of Assets	6.00	10	3.00	5.00	2.00	1.00	31	-6.00	-37	6.00	-8.00	251	-10	-11	5.31	-12	-24	–
Legal Settlements	-61	-220	53	-9.00	-356	-422	-1,401	27	-226	-59	-37	45	-221	-57	-12	-53	-6.19	-33
Pretax Income	367	167	-390	-129	-1,024	-934	-1,837	-4,154	-1,741	-2,435	-155	1,054	-1,314	-394	-18	-236	175	–
Income Tax Expense	247	239	221	83	-87	-375	-54	-10	-4,145	-27	133	174	-451	-278	-178	-28	-1.50	-73
Net Income incl. Noncontrolling Interests	120	-72	-611	-212	-937	-559	-1,783	-4,144	2,404	-2,408	-288	880	-864	-116	160	367	407	200
Minority Interest in Earnings	-37	-26	-19	13	11	1.00	5.00	4.00	0	1.00	4.00	-1.00	2.50	0	0	–	–	–
Net Income	157	-46	-592	-225	-948	-560	-1,788	–	–	–	–	–	–	–	–	–	–	–
Net Income to Common	–	–	–	–	–	-560	-1,788	-4,148	2,404	-2,409	-292	881	-866	-116	160	-208	176	–
EPS (Basic)(per share)	0.42	-0.13	-1.62	-0.62	-2.64	-1.58	-5.08	-11.81	6.86	-6.94	-0.85	2.63	-2.70	-0.38	0.52	-1.06	1.11	1.25
EPS (Diluted)(per share)	0.42	-0.13	-1.62	-0.62	-2.64	-1.58	-5.08	-11.81	6.83	-6.94	-0.85	2.58	-2.70	-0.38	0.49	-1.06	1.11	1.25
Shares Outstanding (Basic, Weighted)(shares)	371	368	365	362	359	355	352	351	350	347	343	335	321	305	305	196	158	160
Shares Outstanding (Diluted, Weighted)(shares)	375	368	365	362	359	355	352	351	352	347	343	342	321	305	326	196	159	160
Dividend per Share(per share)	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.28	0.65	1.50
EBITDA	3,021	2,813	2,227	1,848	2,002	2,501	1,872	435	2,960	2,300	3,994	3,615	1,606	1,066	913	144	330	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 8.1%
Net margin: -10.1%
Return on equity, FY2025: -17.1%

Financial strength

Current ratio: 1.44
Debt to equity: -11.71
Debt to assets: 83.7%
Cash to current liabilities: 40.2%

Valuation

P/E ratio: –
Price to sales: 0.22
Price to book: –
Dividend yield: –